New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 7, 2012
12:50 EDTELOSSyneron Medical shares should be bought, says Maxim
After Syneron Medical reported weaker than expected Q3 operating results, Maxim believes the outlook for the company in Q4 and 2013 appears to be bright. The firm thinks the aesthetic market is rebounding and it reiterates a Buy rating on the stock.
News For ELOS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 25, 2015
07:01 EDTELOSSyneron Medical announces results of clinical trial for Profound
Syneron Medical released the results of a new clinical trial for Profound, an innovative radiofrequency device clinically proven to improve facial and neck wrinkles without surgery. The current results suggest that with optimal settings, a Profound treatment can produce up to 89% of the laxity improvement results of a surgical facelift. With the new protocol for optimal settings to produce superior results, patients can realize many of the benefits approaching the surgical facelift with this novel minimally invasive in-office 30-minute treatment. The breakthrough technology meets the demands of today's consumers. In a recent survey, more than half of women with sagging jaw lines and "turkey necks" have considered nonsurgical treatment. Unlike facelifts, which require general anesthesia, long incisions, and recovery, Profound patients typically experience only minor redness that resolves within two to 12 hours and minimal swelling for up to five days. Most patients can resume normal activities within 24-48 hours.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use